Surface Oncology — Technical Presentation (June 2021)
25 slides from Surface Oncology's technical presentation, Jun 4, 2021
Slide 1: Initial Phase 1 Clinical Data for SRF388 & SRF617
Initial Phase 1 Clinical Data for SRF388 & SRF617 WEBCAST JUNE 4, 2021 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and finan
Slide 3: Today's Highlights
Today’s Highlights Wholly-owned, first-in-class SRF388 (IL-27) demonstrates monotherapy activity and good tolerability – expansions opening Wholly-owned SRF617 (CD39) demonstrates good tolerability, activity in combination – combination expansions enrolling New clinical collaboration with Roche for
Slide 4: SRF388 Targeting IL-27 to Enhance Inflammation in the Tumor Microenvironment
SRF388 Targeting IL-27 to Enhance Inflammation in the Tumor Microenvironment
Slide 5: SRF388: First-in-class IL-27 Antibody with Compelling I-O Rationale
Novel anti-IL-27 antibody that blocks the interaction of IL-27 with its receptor, thereby promoting immune activation in the tumor microenvironment Preclinical models have demonstrated that SRF388 inhibits: IL-27-induced STAT1 phosphorylation in murine and human primary T cells and cell lines IL-27-
Slide 6: SRF388-101: Phase 1, First-in-Human Study Design
SRF388-101: Phase 1, First-in-Human Study Design * 3 RCC backfill slots were enrolled RCC = Renal Cell Carcinoma ccRCC = clear cell Renal Cell Carcinoma HCC = Hepatocellular Carcinoma Patnaik et al ASCO 2021, Abstract 2551, NCT04374877; database snapshot date: April 16, 2021 All dosing q4 weeks
Slide 7: SRF388-101: Baseline Patient Characteristics
SRF388-101: Baseline Patient Characteristics Heavily treated patient population refractory to multiple prior therapeutics All Patients (N=21) Median age, years (range) 66 (46, 83) Sex, n (%) Male Female 7 (33%) 14 (67%) ECOG PS at baseline, n (%) 0 1 6 (29%) 15 (71%) Median time since initial diagno
Slide 8: SRF388-101 Results: Safety and Tolerability
SRF388-101 Results: Safety and Tolerability No DLTs observed; only low-grade related adverse events noted Adverse Event Summary n=21 Treatment-emergent adverse event (TEAE), n (%) Treatment-related AE, n (%) 15 (71%) 4 (19%) Grade ≥3 TEAE, n (%) Grade ≥3 treatment-related AE, n (%) 6 (29%) 0 (0%) Se
Slide 9: SRF388-101 Results: Time on Study
SRF388-101 Results: Time on Study 7 patients remaining on study; 5 able to escalate to higher dose groups Median time on study: 8 weeks (range 1-49) Disease assessment performed at week 8 and then every 12 weeks thereafter Response observed at 8 weeks Patnaik et al ASCO 2021, Abstract 2551, NCT04374
Slide 10: SRF388-101: Monotherapy Activity
SRF388-101: Monotherapy Activity PR observed in patient with NSCLC; 28% with stable disease beyond 16 weeks †1 patient had SD by RECISTv1.1, but experienced overall clinical progression Best Overall Response, n (%) Response Evaluable (n=18) Complete response 0 Partial response 1 (6%) Stable disease
Slide 11: SRF388-101: Evidence of Monotherapy Activity in NSCLC
SRF388-101: Evidence of Monotherapy Activity in NSCLC Confirmed partial response with 66% tumor shrinkage Baseline Week 8 Week 12 Target Lesion 1 Target Lesion 2 Resolved 64-year-old man with squamous cell NSCLC whose disease was resistant to three prior regimens, including chemotherapy and PD-1 blo
Slide 12: Linear PK with Complete Inhibition of Downstream Signaling
Linear PK with Complete Inhibition of Downstream Signaling 10 mg/kg q4 weeks chosen as RP2D 10 mg/kg (n=5) 3 mg/kg (n=6) 1 mg/kg (n=3) 0.3 mg/kg (n=3) 0.1 mg/kg (n=1) 0.03 mg/kg (n=1) Estimated median t1/2 is 12 days Evidence of accumulation and steady state reached by Cycle 3 No evidence of anti-dr
Slide 13: SRF388-101 Study Conclusions
SRF388-101 Study Conclusions Support further evaluation as monotherapy and combination therapy SRF388 is well tolerated at all doses tested to date Preliminary results show promising single-agent activity even in heavily pre-treated patients: Confirmed PR in a patient with squamous cell NSCLC whose
Slide 14: SRF617 Targeting CD39 for Dual Immune System Activation
SRF617 Targeting CD39 for Dual Immune System Activation
Slide 15: Significance of CD39 in Immuno-oncology
Significance of CD39 in Immuno-oncology Key enzyme modulating innate and adaptive immune responses Extracellular adenosine suppresses tumor immunity Extracellular ATP stimulates innate immunity Decreased Decreased Increased CD39 inhibition decreases AMP/adenosine and increases ATP in the TME
Slide 16: SRF617-101: Phase 1, First-in-Human Study Design
SRF617-101: Phase 1, First-in-Human Study Design * Includes biopsy backfill slots **Clinical collaboration with Merck NCT04336098; database snapshot date April 9, 2021. Dosing is q2 weeks
Slide 17: SRF617-101: Baseline Patient Characteristics, Monotherapy
SRF617-101: Baseline Patient Characteristics, Monotherapy Heavily treated patient population refractory to multiple prior therapeutics All Patients (N-27) Median age, years (range) 65 (20, 80) Sex, n (%) Male Female 10 (37%) 17 (63%) ECOG PS at baseline, n (%) 0 1 11 (41%) 16 (59%) Median time since
Slide 18: SRF617-101 Results: Safety and Tolerability
*TEAE defined as an adverse event that emerges or worsens in the period from the first dose of SRF617 to 30 days after the last dose. Adverse Event Summary n=27 Treatment-emergent adverse event* (TEAE), n (%) Treatment-related AE, n (%) 23 (85%) 14 (52%) Grade ≥3 TEAE, n (%) Grade ≥3 treatment-relat
Slide 19: SRF617-101 Results: Monotherapy Time on Study
Progressive Disease Prior α-PD-(L)1 therapy Patient Continuing DL1 (20 mg) DL2 (70 mg) DL3 (200 mg) DL4 (700 mg) DL5 (1400 mg) NCT04336098; database snapshot date April 9, 2021. Median time on study: 8 weeks (range 1-43 weeks) Disease assessment performed at week 8 and then every 8 weeks thereafter
Slide 20: SRF617-101: Early Data from Combination Cohorts
SRF617-101: Early Data from Combination Cohorts SRF617 + Gem/Abraxane Cohort * Five patients dosed with SRF617 (200 mg) + full-dose gemcitabine/Abraxane; four with follow-up beyond one cycle Adverse events as expected, with reported bone marrow suppression and diarrhea One unconfirmed Partial Respon
Slide 21: SRF617-101: Evidence of Combination Activity
SRF617-101: Evidence of Combination Activity Partial response in patient with pancreatic cancer 60-year-old man with pancreatic cancer with liver metastases receiving 200 mg SRF617 + gemcitabine/Abraxane Progressive disease on prior FOLFIRINOX treatment Unconfirmed PR with ~ 50% tumor shrinkage afte
Slide 22: SRF617 Study Conclusions
SRF617 monotherapy is well tolerated at all tested doses to date in patients with advanced solid tumors and has a positive profile for intended combinations Early results support further evaluation: Monotherapy: 7 of 19 evaluable patients (37%) had disease stabilization at eight weeks with four (21%
Slide 23: Clinical Collaboration Agreement with Roche
Clinical Collaboration Agreement with Roche Strong non-clinical and translational data for SRF388 in immuno-oncology-naive hepatocellular carcinoma (HCC) Current standard of care in first-line, immuno-oncology-naive HCC is the combination of atezolizumab (Roche’s anti-PD-L1 Tecentriq®) with bevacizu
Slide 24: Reviewing Today's Highlights
Reviewing Today’s Highlights Wholly-owned, first-in-class SRF388 (IL-27) demonstrates monotherapy activity, good tolerability, expansions opening Wholly-owned SRF617 (CD39) demonstrates good tolerability, activity in combination – combination expansions enrolling New clinical collaboration with Roch
Slide 25: Thank You
Thank You %
Surface Oncology — Technical Presentation (June 2021) on 6ix